Glycoprotein IIb/IIIa Inhibitors during Rescue Percutaneous Coronary Intervention in Acute Myocardial Infarction

Volume 18 - Issue 2 - February, 2006
Posted on: 8/1/08
0 Comments
2864 reads

Author(s):

Luis Gruberg, MD, Mahmoud Suleiman, MD, Michael Kapeliovich, MD, Haim Hammerman, MD, Ehud Grenadier, MD, Monther Boulus, MD, Shlomo Amikam, MD, Walter Markiewicz, MD, Rafael Beyar, MD

Fibrinolytic therapy for acute myocardial infarction, even with the most efficient regimens available, is fraught with a substantial proportion of failures to re-establish normal blood flow in the occluded vessel.^1,2 Failure to achieve prompt and complete restoration of TIMI 3 coronary blood flow after full-dose thrombolysis is associated with a poor prognosis.³ Although percutaneous coronary intervention (PCI), with or without stenting following full-dose thrombolytic therapy (rescue angioplasty), is a common procedure in these patients, data are scarce and there is ample controversy regarding the usefulness of the procedure.^4–6 Moreover, few data are available concerning the safety and efficacy of stenting in combination with glycoprotein (GP) IIb/IIIa inhibitors administration in these patients.^7–9 Even recent studies have failed to address the issue of GP IIb/IIIa inhibitor administration in these patients.¹⁰ The aim of the present study was to assess the impact of concomitant treatment with GP IIb/IIIa inhibitors on the clinical outcomes of acute myocardial infarction patients who underwent rescue PCI with stents.